Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (121-130 of 190) with videos related to

Pageof 19
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2002
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemiaBorje S Andersson, Peter F Thall, Timothy Madden, et al.
Stroke|July 12, 2008
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in childrenHarry T Whelan, John D Cook, Catherine M Amlie-Lefond, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2019
In Reply to Krishnatry and ManjaliMark J Amsbaugh, Anita Mahajan, Peter F Thall, et al.
International Journal of Radiation Oncology, Biology, Physics|January 6, 2019
A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine GliomaMark J Amsbaugh, Anita Mahajan, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaPaul M Armistead, Marcos de Lima, Sherry Pierce, et al.
Transplantation|October 27, 2009
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantationStefan O Ciurea, Marcos de Lima, Pedro Cano, et al.
International Journal of Radiation Oncology, Biology, Physics|August 8, 2012
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancerSteven H Lin, Lu Wang, Bevan Myles, et al.
Blood|May 31, 2002
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideElihu H Estey, Peter F Thall, Francis J Giles, et al.
Cancer|March 7, 2006
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylateDejka M Steinert, Mauricio Oyarzo, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylateJohn C McAuliffe, Alexander J F Lazar, Dan Yang, et al.
Pageof 19

Showing results (121-130 of 190) with videos related to

Sort By:
Pageof 19
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2002
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemiaBorje S Andersson, Peter F Thall, Timothy Madden, et al.
Stroke|July 12, 2008
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in childrenHarry T Whelan, John D Cook, Catherine M Amlie-Lefond, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2019
In Reply to Krishnatry and ManjaliMark J Amsbaugh, Anita Mahajan, Peter F Thall, et al.
International Journal of Radiation Oncology, Biology, Physics|January 6, 2019
A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine GliomaMark J Amsbaugh, Anita Mahajan, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaPaul M Armistead, Marcos de Lima, Sherry Pierce, et al.
Transplantation|October 27, 2009
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantationStefan O Ciurea, Marcos de Lima, Pedro Cano, et al.
International Journal of Radiation Oncology, Biology, Physics|August 8, 2012
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancerSteven H Lin, Lu Wang, Bevan Myles, et al.
Blood|May 31, 2002
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideElihu H Estey, Peter F Thall, Francis J Giles, et al.
Cancer|March 7, 2006
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylateDejka M Steinert, Mauricio Oyarzo, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylateJohn C McAuliffe, Alexander J F Lazar, Dan Yang, et al.
Pageof 19